宁波毓昌生物技术有限公司于 2018 年 4 月在宁海设立,注册资本 2840 万元。公司基于多糖结合疫苗技术、毕赤酵母重组表达技术
和大肠杆菌重组表达技术三大技术平台专注于生物药的研发,包括人 用疫苗、重组蛋白和抗肿瘤药三大类产品。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows